Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, reported its financial results for the fourth quarter and full year ended December 31, 2013. Corcept Therapeutics Incorporated (NASDAQ:CORT) shares after opening at $3.87 moved to $4.40 on last trade day and at the end of the day closed at $4.07. Company price to sales ratio in past twelve months was calculated as 39.07 and price to cash ratio as 7.40. Corcept Therapeutics Incorporated (NASDAQ:CORT) showed a negative weekly performance of 1.21%.
Biostar Pharmaceuticals Inc (NASDAQ:BSPM) saw a sudden rise to end the day 13.93% higher with no company-specific news to point for the activity. International stocks trading in New York closed higher Thursday, with the Bank of New York index of American depositary receipts adding 0.6% to 151.30. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) shares advanced 5.26% in last trading session and ended the day on $2.00. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) return on equity ratio is recorded as -9.90% and its return on assets is -8.30%. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) yearly performance is 108.33%.
Lumenis Ltd. (NASDAQ: LMNS) came public on Thursday at an IPO price of $12.50, well below its expected range of $15 to $17. The Israel-based maker of minimally invasive clinical solutions for surgical, ophthalmic and aesthetic applications offered 6.25 million class B ordinary shares and underwriters have a 30-day option on an additional 937,500 shares. The company’s other class of shares are called simply “ordinary” shares and carry no additional voting or other privileges. The “ordinary” shares will automatically convert to class B shares when the lock-up period ends, 181 days after the IPO. Shares closed at $12.15 on the stock’s IPO day and at $12.20 on Friday. Shares peaked at $13.38 early Thursday morning. Lumenis Ltd (NASDAQ:LMNS) shares moved up 5.01% in last trading session and was closed at $10.68, while trading in range of $ 10.10 – 10.81. Lumenis Ltd (NASDAQ:LMNS) year to date (YTD) performance is -12.10%.
Trevena Inc (NASDAQ:TRVN) +11.36% , a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, announced financial results for the year ended December 31, 2013. Trevena Inc (NASDAQ:TRVN) weekly performance is -4.85%. On last trading day company shares ended up $7.45. Trevena Inc (NASDAQ:TRVN) distance from 50-day simple moving average (SMA50) is -4.79%. Analysts mean target price for the company is $14.80.
Leave a Reply